Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative therapies operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these substances increase insulin production and re

The management of diabetes continues to evolve with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising strategies for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes.